Gesynta Pharma AB Revenue and Competitors

Gesynta Pharma's drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. \n\nGesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy.\n\nGesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain.\n\nGesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.